City
Epaper

No definitive agreement on commercial supplies with Moderna: Cipla

By IANS | Updated: June 29, 2021 21:55 IST

New Delhi, June 29 There is no definitive agreement yet between Cipla and US major Moderna on commercial ...

Open in App

New Delhi, June 29 There is no definitive agreement yet between Cipla and US major Moderna on commercial supplies of Covid 19 vaccines, Cipla said on Tuesday.

Cipla said it is helping Moderna with approvals and imports of vaccines to be donated to India.

"Cipla Limited is supporting Moderna, Inc. with the regulatory approval and importation of vaccines to be donated to India. At this stage, there is no definitive agreement on commercial supplies", Cipla said in a statement to .

Moderna Inc, a biotechnology company pioneering messenger RNA

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: usNew DelhiCipla limitedThe new delhi municipal councilDelhi south-westCiplaCipla ltd.
Open in App

Related Stories

InternationalUS Government Shutdown: US Embassy in India’s X Account to Pause Regular Updates Until Full Operations Resume

CricketIND-W vs AUS-W, 3rd ODI: Australia Women Win Toss, Opt to Bat Against India in Series Decider; Check Playing XIs

CricketWhy Is India Women’s Cricket Team Wearing a Pink Jersey in IND-W vs AUS-W 3rd ODI 2025 Match?

CricketIND-W vs AUS-W 3rd ODI LIVE Cricket Streaming: When and Where to Watch India Women vs Australia Women Final Match

InternationalIndian-Origin Man Beheaded In US In Front Of Family After Violent Dispute

Health Realted Stories

HealthIndia’s MedTech sector projected to touch $50 billion by 2030: Dr Jitendra Singh

HealthCentre issues advisory to states on cough syrup deaths; urges its rational use in children

HealthEbola virus strain found in semen, breast milk months after infection: Study

HealthDeadly brain cancer can alter skull, immune response: Study

Health‘Mirror, Mirror in the Lab’, BRIC-RGCB scientists build tiny nanopores to spot diseases early